SecBot SecBot

VIVS

VivoSim Labs, INC.
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0001497253 Biotech & Drug Discovery
$0.1500 −0.01 (−6.25%)
Oct 23 4:00 PM ET · prev $0.1600
Market cap
$2.6M
Nano cap
1 year
−93.6%
from $2.33 · Oct 24
30 days
−34.8%
from $0.2300
52-week range
$0.1500–2.98
at the low
Avg volume 20D
929.8K
Oct 15 spike 3.51M
Short interest
707.9K
≈4.3% of shares · +25.4%
Days to cover
1.0
at average volume
Insider net
+$2.8K
1 buyer · 0 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
7
analyzed by SecBot
SecBot read BEARISH 5 reports · 90 days
Balance 2 bearish · 0 bullish · 1 mixed · 2 neutral oldest → newest, height = score
Avg score ·High conf. 3/5 ·Next Earnings date, Nov 4, 2026
Strongest BEARISH VivoSim Labs' wholly-owned subsidiary Organovo, Inc. amended its lease to reduce office space by vacating…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    1 insider bought $2.8K at an average $0.2804. No open-market sales. Price is 47% below their cost.

  • InstitutionsBEARISH

    Q2 2026: 0 added (0 new), 3 trimmed or exited.

  • Short sellersBUILDING

    Short interest +25.4% to 707.9K shares. 1.0 days to cover, ≈4.3% of shares.

  • TrendDOWNTREND

    37% below its 50-day average. New closing low $0.1500 on Oct 23.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
ROYAL BANK OF CANADATRIM1—
GEODE CAPITAL MANAGEMENT, LLCTRIM25,976$27.8K
UBS Group AGNEAR_EXIT18$20.00
GEODE CAPITAL MANAGEMENT, LLCADD36,850$52.7K
CITIGROUP INCADD6,504$9.3K
UBS Group AGDOUBLED952$1.4K
MORGAN STANLEYTRIM50$72.00
TWO SIGMA INVESTMENTS, LPTRIM11,830$21.4K

Quarterly 13F filings are due 45 days after each quarter ends.

Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 4, 2026
Earnings date
🔒 Fresh data — subscribers only
Recent
Sep 16, 2026
FDA
VivoSim Labs Unveils New NAMkind™ Drug Toxicity Data at EUROTOX 2026, Demonstrating Predictive Superiority in Liver and Gastrointestinal Safety Across Small Molecules and ADCs
New data presented in Vienna highlights long-term repeat-dose modeling, mechanistic GI barrier profiling, and deconvolution of payload- and…
Sep 1, 2026
Press release
VivoSim Labs to Add Rat Liver Model to NAMkind Platform
New cross-species capability is designed to help pharma distinguish rat-specific liver toxicity from risks that may translate to humans New…
Aug 25, 2026
Listing
Listing Status: VIVS — Deficient (was Normal)
VivoSim Labs, Inc. - Common Stock | Nasdaq Financial Status Indicator N → D
Aug 10, 2026
Earnings date
VIVS Q1 2026 Earnings Before Market Open — 2026-08-10
Aug 6, 2026
Activist
VivoSim Provides Financial and Listing Compliance Update
SAN DIEGO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New…

Insider ledger

Form 4
$2.8K
bought · 1 insider
$0
sold · 0 insiders
−46.5%
vs their $0.2804 cost
DateInsiderTypeValue
Aug 31, 2026
Lialin Tony Serge
Chief Commercial Officer
BUY$2.8K

Earnings setup

Estimates

Revision history: 🔒 Fresh data — subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data — subscribers only
Next Q🔒 Fresh data — subscribers only
Current FY🔒 Fresh data — subscribers only
Next FY🔒 Fresh data — subscribers only

Short side

FINRA· Sep 30, 2026
707,866
shares short
+25.4%
vs prior settlement
1.0
days to cover
≈4.3%
of shares outstanding
Trading halts
Jul 15, 2026Volatility PauseResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 16, 2026 SEC
VivoSim Labs' wholly-owned subsidiary Organovo, Inc. amended its lease to reduce office space by vacating Suite 202…
8-K — Impact 5/10
Oct 6, 2026 SEC
VivoSim Labs held its 2026 Annual Meeting on September 30, 2026. Stockholders approved a 3,165,000-share increase to…
8-K — Impact 4/10
Sep 16, 2026 Press
VivoSim Labs presented new clinical benchmark data at EUROTOX 2026 demonstrating its NAMkind™ 3D human liver and…
Impact 5/10
Sep 16, 2026 FDA
VivoSim Labs Unveils New NAMkind™ Drug Toxicity Data at EUROTOX 2026, Demonstrating Predictive Superiority in Liver and Gastrointestinal Safety Across Small Molecules and ADCs
New data presented in Vienna highlights long-term repeat-dose modeling, mechanistic GI barrier profi
Aug 31, 2026 Insider
Lialin Tony Serge bought 10,000 shares
Chief Commercial Officer @ $0.2804 ($2.8K)
Aug 11, 2026 SEC
VivoSim Labs' S-1 registration statement (File No. 333-297892) for a best-efforts public offering of up to $4,000,000…
EFFECT — Impact 7/10
Jun 30, 2026 Inst.
ROYAL BANK OF CANADA — TRIM
1 shares (—)
Jun 30, 2026 Inst.
GEODE CAPITAL MANAGEMENT, LLC — TRIM
25,976 shares ($27.8K)

SecBot reports

7 filings · 2 press releases · 0 bullish · 3 bearish · 1 mixed · 3 neutral
All VIVS filing & press-release reports (9)